AGP Executive Report
Last update: 2 hours agoEye Health Research: Iceland-listed Oculis says recruitment is complete for a late-stage trial of licaminlimab for dry eye disease, with results expected around year-end 2026. Wellness Tourism: Blue Lagoon’s operator plans a $115 million Reykjavík IPO to fund expansion as demand for geothermal wellness travel grows. Cancer Care: Oncologist Helgi Hafsteinn Helgason of South Iceland Healthcare Institution says a personalized mRNA vaccine, designed from each patient’s melanoma, is raising hopes of reducing cancer recurrence after surgery. The approach is still under study.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.